ERBB2 and neoplasm: Among patients with differentiated EGC (316/680, 46.5%), those with HER2 overexpression (29/316, 9.2%) did not show clinically significant differences compared with HER2-negative patients (177/316, 56.0%) in terms of age, sex, tumour size, location, gross type, depth of invasion, presence of LVI, and presence of LNM.